With com­pe­ti­tion on its heels, Blue­print takes three can­cer drugs to Chi­na

Blue­print Med­i­cines $BPMC is cash­ing in on the chance to take three of its in­ves­ti­ga­tion­al can­cer ther­a­pies to Chi­na, ink­ing a deal with CStone Phar­ma­ceu­ti­cals that gives the Shang­hai-based com­pa­ny rights to de­vel­op and com­mer­cial­ize the drugs re­gion­al­ly.

The deal gets Blue­print an up­front pay­ment of $40 mil­lion, along with $346 mil­lion in po­ten­tial mile­stones. CStone gets the OK to de­vel­op and sell the meds in Chi­na, Hong Kong, Macau, and Tai­wan — both as stand­alone ther­a­pies or com­bos.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.